FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220660147> ?p ?o ?g. }

• W4220660147 endingPage "955" @default.
• W4220660147 startingPage "935" @default.
• W4220660147 abstract "Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are chronic immune-mediated inflammatory diseases (IMIDs) associated with cardiovascular (CV) disease. High-sensitivity C-reactive protein (hsCRP) and, more recently, the neutrophil–lymphocyte ratio (NLR) are important inflammatory biomarkers predictive of CV disease and CV disease-associated mortality. Here, we report the effect of interleukin (IL)-17A inhibition with secukinumab on CV risk parameters in patients with psoriasis, PsA, and axSpA over 1 year of treatment. This was a post hoc analysis of pooled data from phase 3/4 secukinumab studies in psoriasis, PsA, and axSpA. CV-related exclusion criteria included uncontrolled hypertension and congestive heart failure. Traditional risk factors assessed were body mass index (BMI) > 25, high fasting glucose and blood pressure (systolic and diastolic), and high cholesterol (low-density lipoproteins [LDL], total cholesterol/HDL ratio, and triglycerides). Inflammatory CV risk parameters assessed were hsCRP and NLR. Statistical analysis was descriptive. Subgroup analyses were performed in high-risk patients defined as having baseline hsCRP > 4 mg/L (patients with psoriasis) and > 10 mg/L (patients with PsA/axSpA). In total, 9197 patients from 19 clinical trials (8 in psoriasis, n = 4742; 5 in PsA, n = 2475; 6 in axSpA, n = 1980) were included. All traditional CV risk parameters remained stable in secukinumab-treated patients through 1 year. Secukinumab rapidly reduced both hsCRP and the NLR compared with placebo at week 12 (psoriasis) or week 16 (PsA/axSpA) in the overall population and in high-risk patients (all P < 0.01). This reduction was maintained for at least 1 year of secukinumab therapy in all indications. Secukinumab led to a rapid and sustained reduction in hsCRP and the NLR in patients with IMIDs with a high systemic inflammatory burden. Traditional CV risk factors remained stable for at least 1 year in patients with psoriasis, PsA, and axSpA. Taken together, secukinumab had a favorable effect on systemic inflammation without impact on traditional CV risk factors. ClinicalTrials.gov, NCT01365455, NCT01358578, NCT01406938, NCT01555125, NCT01636687, NCT02752776, NCT02074982, NCT02826603, NCT01752634, NCT01989468, NCT02294227, NCT02404350, NCT02745080, NCT01863732, NCT01649375, NCT02008916, NCT02159053, NCT02896127, NCT02696031." @default.
• W4220660147 created "2022-04-03" @default.
• W4220660147 creator A5015084747 @default.
• W4220660147 creator A5032343592 @default.
• W4220660147 creator A5037356234 @default.
• W4220660147 creator A5047076464 @default.
• W4220660147 creator A5071482630 @default.
• W4220660147 creator A5073324135 @default.
• W4220660147 creator A5074725547 @default.
• W4220660147 creator A5082404954 @default.
• W4220660147 creator A5086804964 @default.
• W4220660147 date "2022-03-19" @default.
• W4220660147 modified "2023-10-17" @default.
• W4220660147 title "Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications" @default.
• W4220660147 cites W1211317749 @default.
• W4220660147 cites W1526387844 @default.
• W4220660147 cites W1999171824 @default.
• W4220660147 cites W2010964474 @default.
• W4220660147 cites W2062355011 @default.
• W4220660147 cites W2068985697 @default.
• W4220660147 cites W2075619622 @default.
• W4220660147 cites W2082564973 @default.
• W4220660147 cites W2084527669 @default.
• W4220660147 cites W2088078494 @default.
• W4220660147 cites W2096809109 @default.
• W4220660147 cites W2106641131 @default.
• W4220660147 cites W2128363109 @default.
• W4220660147 cites W2146444857 @default.
• W4220660147 cites W2163092745 @default.
• W4220660147 cites W2440713342 @default.
• W4220660147 cites W2540989688 @default.
• W4220660147 cites W2568758989 @default.
• W4220660147 cites W2569499583 @default.
• W4220660147 cites W2614065762 @default.
• W4220660147 cites W2748400555 @default.
• W4220660147 cites W2766721878 @default.
• W4220660147 cites W2781439741 @default.
• W4220660147 cites W2789226593 @default.
• W4220660147 cites W2794158529 @default.
• W4220660147 cites W2799473857 @default.
• W4220660147 cites W2804996442 @default.
• W4220660147 cites W2899847452 @default.
• W4220660147 cites W2902033804 @default.
• W4220660147 cites W2902932442 @default.
• W4220660147 cites W2912436760 @default.
• W4220660147 cites W2947452967 @default.
• W4220660147 cites W2963660305 @default.
• W4220660147 cites W2966206928 @default.
• W4220660147 cites W2979709352 @default.
• W4220660147 cites W2984486845 @default.
• W4220660147 cites W2991538871 @default.
• W4220660147 cites W2999565226 @default.
• W4220660147 cites W3005779461 @default.
• W4220660147 cites W3008728180 @default.
• W4220660147 cites W3009872190 @default.
• W4220660147 cites W3027042229 @default.
• W4220660147 cites W3084590513 @default.
• W4220660147 cites W3092823303 @default.
• W4220660147 cites W3113919193 @default.
• W4220660147 cites W3114911722 @default.
• W4220660147 cites W3119981920 @default.
• W4220660147 cites W3174424817 @default.
• W4220660147 cites W3197657657 @default.
• W4220660147 doi "https://doi.org/10.1007/s40744-022-00434-z" @default.
• W4220660147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35305260" @default.
• W4220660147 hasPublicationYear "2022" @default.
• W4220660147 type Work @default.
• W4220660147 citedByCount "4" @default.
• W4220660147 countsByYear W42206601472022 @default.
• W4220660147 countsByYear W42206601472023 @default.
• W4220660147 crossrefType "journal-article" @default.
• W4220660147 hasAuthorship W4220660147A5015084747 @default.
• W4220660147 hasAuthorship W4220660147A5032343592 @default.
• W4220660147 hasAuthorship W4220660147A5037356234 @default.
• W4220660147 hasAuthorship W4220660147A5047076464 @default.
• W4220660147 hasAuthorship W4220660147A5071482630 @default.
• W4220660147 hasAuthorship W4220660147A5073324135 @default.
• W4220660147 hasAuthorship W4220660147A5074725547 @default.
• W4220660147 hasAuthorship W4220660147A5082404954 @default.
• W4220660147 hasAuthorship W4220660147A5086804964 @default.
• W4220660147 hasBestOaLocation W42206601471 @default.
• W4220660147 hasConcept C126322002 @default.
• W4220660147 hasConcept C203014093 @default.
• W4220660147 hasConcept C2776260265 @default.
• W4220660147 hasConcept C2776914184 @default.
• W4220660147 hasConcept C2778163477 @default.
• W4220660147 hasConcept C2778270857 @default.
• W4220660147 hasConcept C2779134260 @default.
• W4220660147 hasConcept C2779786854 @default.
• W4220660147 hasConcept C2780564577 @default.
• W4220660147 hasConcept C2781195455 @default.
• W4220660147 hasConcept C2908647359 @default.
• W4220660147 hasConcept C67761136 @default.
• W4220660147 hasConcept C71924100 @default.
• W4220660147 hasConcept C90924648 @default.
• W4220660147 hasConcept C99454951 @default.
• W4220660147 hasConceptScore W4220660147C126322002 @default.
• W4220660147 hasConceptScore W4220660147C203014093 @default.

• next